



**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Microsoft Teams webinar.
Tuesday, January 21, 2025
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In
<p>Join the meeting now</p> <p>Meeting ID: 252 322 420 505 Passcode: Vo9JX9oX</p> <p>Download Teams Join on the web</p>	<p style="text-align: center;">+1-858-252-2734 (US Toll)</p> <p style="text-align: center;">Phone Conference ID: 453 137 721#</p>

AGENDA

- I. **Call to Order and Welcome**
- II. **Executive Session (upon request)**
- III. **Old Business**
 - a. Approval of April 2024 Meeting Minutes
 - b. Approval of July 2024 Meeting Minutes
 - c. Approval of October 2024 Meeting Minutes
- IV. **New Business**
 - a. New Products to Market to be Reviewed as Single Products:
 - i. Cobenfy™ (*Antipsychotics, Second Generation (Atypical) and Injectable*)
 - ii. Livdelzi® (*Bile Salts*)
 - iii. Vyalev™ (*Parkinson’s Disease (Antiparkinson’s Agents)*)
 - iv. Ebglyss™ (*Immunomodulators – Atopic Dermatitis*)
 - v. Xdemvy™ (*Non-PDL*)
 - vi. Yorvipath™ (*Non-PDL*)
 - vii. Duvyzat™ (*Muscular Dystrophy Agents*)
 - viii. Nemluvio® (*Immunomodulators, Atopic Dermatitis*)
 - ix. Neffy® (*Epinephrine, Self-Injectable*)
 - x. Miplyffa™ (*Non-PDL*)
 - xi. Aqneursa™ (*Non-PDL*)



V. Therapeutic Classes with Recommended Changes

- a. Antibiotics: Gastrointestinal
- b. Antibiotics: Vaginal
- c. Antibiotics: Penicillins
- d. Antibiotics: Sulfonamides, Folate Antagonists
- e. Antifungals, Oral
- f. Hepatitis C Agents: Interferons and Ribavirins
- g. Chronic Obstructive Pulmonary Disease (COPD) Agents
- h. Epinephrine, Self-Injectable
- i. Glucocorticoids, Inhaled

VI. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> • Antibiotics, Cephalosporins 1st Generation • Antibiotics, Cephalosporins 2nd Generation • Antibiotics, Cephalosporins 3rd Generation • Antibiotics, Inhaled • Antibiotics, Macrolides • Antibiotics, Oxazolidinones • Antibiotics, Quinolones • Antibiotics, Tetracyclines • Antihistamines, Minimally Sedating 	<ul style="list-style-type: none"> • Antiretrovirals, HIV/AIDS • Antivirals (Oral), Herpes • Antivirals (Oral), Influenza • Bronchodilators, Beta-Agonist • Hepatitis B Agents • Hepatitis C Agents: Direct-Acting Antivirals • Intranasal Rhinitis Agents • Leukotriene Modifiers
--	--

VII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. **April 15, 2025**
 - ii. **July 15, 2025**
 - iii. **October 14, 2025**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.